Diabetes drug shows promise in preventing deadly transplant complication
NCT ID NCT05149365
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether sitagliptin, a diabetes medicine, could prevent acute graft-versus-host disease (GVHD) in 190 adults receiving stem cell transplants from related or unrelated donors. Participants took sitagliptin along with standard GVHD prevention. The main goal was to see if it reduced moderate-to-severe GVHD within 100 days after transplant. The trial also monitored side effects, infections, and survival for one year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
Suzhou, Jiangsu, 215000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Can a Life-Saving transplant leave hidden scars on a Child's mind?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Frailty check may steer safer cancer care for seniors
- Could gratitude exercises aid blood cancer recovery?
- Can a new tracer light up cancer growth?